MedPath

Evaluation of an Automated Physician-Directed Messaging on Patient Engagement in the Digital Diabetes Prevention Program

Not Applicable
Active, not recruiting
Conditions
Pre Diabetes
Interventions
Other: Digital diabetes prevention program (dDPP)
Other: Adapted dDPP-EHR tool
Registration Number
NCT04773834
Lead Sponsor
NYU Langone Health
Brief Summary

This study aims to understand the effects of automated physician directed messaging on patient engagement in the digital diabetes prevention program (dDPP). The messages are tailored to patient engagement levels based on established engagement thresholds, which are based on the patient's use of the dDPP application. The system is designed to minimize work for providers by sending automated targeted messages to patients to potentially increase engagement, prevent onset of diabetes and improve clinical outcomes. The patients in the study are automatically nudged using a combination of text messaging and MyChart messaging.

Detailed Description

Using a mixed-methods design, this study will be completed in three phases. For Phase 3, we aim to conduct a randomized control trial with 400 patients with pre-diabetic, all of whom will be using the dDPP application. Half of enrolled patients will be randomized to the intervention group and receive automated targeted messaging.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
490
Inclusion Criteria
  • 18 years or older, BMI ≥ 25 kg/m2 (> 22 kg/m2 if self-identified as Asian)
  • Must be a NYU Langone patient
  • A diagnosis of prediabetes (either diagnosis of prediabetes or an HbA1C level of 5.7%-6.4% in past 12 months) or diabetes risk factors (BMI ≥ 25 kg/m2 or > 22 kg/m2 if self-identified as Asian
  • Safe to engage in moderate physical exercise (as determined by their PCP)
  • Sufficient English to be able to complete the enrollment process
  • Has app-capable device with data to use the dDPP application and receive text messages
Exclusion Criteria
  • Diagnosed with diabetes
  • Patients whose weight may vary considerably over the study's timeframe for reasons other than the intervention (e.g. cancer, pregnancy, ascites, severe CHF)
  • Patients with severe psychiatric disease or dementia
  • Active health condition that prevents them from engaging in moderate exercise

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Experimental groupAdapted dDPP-EHR toolParticipants will be enrolled virtually into a digital diabetes prevention program through the Noom app and willing to receive text messages based on their engagement levels in Noom from the study team, as well as complete text-based surveys.
Control groupDigital diabetes prevention program (dDPP)Participants will be enrolled virtually into the digital diabetes prevention program through the Noom app and willing to receive general text messages from the study team
Experimental groupDigital diabetes prevention program (dDPP)Participants will be enrolled virtually into a digital diabetes prevention program through the Noom app and willing to receive text messages based on their engagement levels in Noom from the study team, as well as complete text-based surveys.
Primary Outcome Measures
NameTimeMethod
Body Mass Index (BMI) (kg/m2)through completion of dDPP program (average 1 year)

BMI will be calculated using height (m) from electronic health records and weight (kg) from remote Bluetooth-connected weight scales. Data will be collected at discrete time points: 0 month (at enrollment), 3 months, 6 months, 9 months, 12 months (study completion)

Hemoglobin A1c (HbA1c) level (mmol/mol)through completion of dDPP program (average 1 year)

Repeated measurements of participant HbA1c will be taken via HbA1C home test kit and electronic health records. Data will be collected at discrete time points: 0 month (at enrollment), 6 months, 12 months (study completion)

Body Weight (kilograms)through completion of dDPP program (average 1 year)

Repeated measurements of participant weight will be taken via remote Bluetooth-connected weight scales, measured in light clothing without shoes. Data will be collected at discrete time points: 0 month (at enrollment), 3 months, 6 months, 9 months, 12 months (study completion)

Secondary Outcome Measures
NameTimeMethod
dDPP platform user log-insthrough completion of dDPP program (average 1 year)

Perceptions of patient engagement will be collected via surveys from patients measured using data on number of dDPP logins, as provided from the Noom platform

dDPP platform meal log (food item and calories/day)through completion of dDPP program (average 1 year)

Perceptions of patient engagement will be collected via surveys from patients using data on number of completed meal logs, as provided from the Noom platform

dDPP platform lesson plans completedthrough completion of dDPP program (average 1 year)

Perceptions of patient engagement will be collected via surveys from patients using the number of completion of weekly lesson plans, as provided from the Noom platform

dDPP platform group social posts sentthrough completion of dDPP program (average 1 year)

Perceptions of patient engagement will be collected via surveys from patients using data on number of messages to online social groups, as provided from the Noom platform

dDPP platform step log (steps/day)through completion of dDPP program (average 1 year)

Perceptions of patient engagement will be collected via surveys from patients using data on number of completed platform step logs, as provided from the Noom platform

dDPP platform coach messages sentthrough completion of dDPP program (average 1 year)

Perceptions of patient engagement will be collected via surveys from patients using data on number of messages to coaches as provided from the Noom platform

dDPP platform exercise log (min)through completion of dDPP program (average 1 year)

Perceptions of patient engagement will be collected via surveys from patients using data on number of completed platform exercise logs, as provided from the Noom platform

Trial Locations

Locations (1)

NYU Langone Health

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath